SWOG clinical trial number
SWOG-9101
Evaluation of Edatrexate in Patients with Advanced or Recurrent Bladder Carcinoma, Phase II
Closed
Phase
Accrual
15%
Abbreviated Title
Evaluation of Edatrexate in Patients with Advanced or Recurrent Bladder Carcinoma, Phase II
Activated
11/15/1992
Closed
11/15/1993